Woodhouse Kristen L, Li Jun-Xu
Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY.
bioRxiv. 2025 Jun 27:2025.06.25.661558. doi: 10.1101/2025.06.25.661558.
Recent work in animals suggests xylazine neither enhances the rewarding effects nor intake of fentanyl. Anecdotal evidence from people who use drugs indicates some individuals prefer fentanyl adulterated with xylazine. Systematic examination of pharmacological interactions between xylazine and opioids is needed to understand the disparate findings between preclinical studies and human reports.
This study examined behavioral interactions between xylazine and opioids in rats to investigate the pharmacology underlying an emerging trend in drug use.
The sedative, hypothermic, subjective, and respiratory effects of xylazine and opioid-xylazine mixtures were examined in male rats. Locomotor activity was measured in an open field, and body temperature changes were measured with a rectal probe. Rats were trained to discriminate 0.04 mg/kg fentanyl, 0.02 mg/kg fentanyl, or 1.5 mg/kg xylazine from saline and were probed with fentanyl, xylazine, or both to observe whether the drug(s) generalized with the training dose. Whole body plethysmography was used to assess the effects of xylazine on respiration.
Xylazine depressed locomotor activity and core body temperature, but considerable variability between subjects was observed. In some subjects, xylazine fully substituted for fentanyl, and prolonged the subjective effects of fentanyl. Doses of 1 and 1.78 mg/kg xylazine only partially generalized to the training dose of 1.5 mg/kg xylazine. Xylazine exacerbated the respiratory depressant effects of opioids, and atipamezole reversed the xylazine enhancement of morphine-induced respiratory depression.
Individual differences were observed in multiple behavioral measures following xylazine administration and may recapitulate the divisiveness of xylazine reported in people who use drugs.
近期动物实验表明,赛拉嗪既不会增强芬太尼的奖赏效应,也不会增加其摄入量。吸毒者的轶事证据表明,一些人更喜欢掺有赛拉嗪的芬太尼。需要系统研究赛拉嗪与阿片类药物之间的药理相互作用,以理解临床前研究与人类报告之间存在差异的结果。
本研究检测了赛拉嗪与阿片类药物在大鼠中的行为相互作用,以探究吸毒新趋势背后的药理学机制。
检测了赛拉嗪及阿片类药物-赛拉嗪混合物对雄性大鼠的镇静、体温降低、主观及呼吸效应。在旷场中测量运动活性,用直肠探头测量体温变化。训练大鼠区分0.04mg/kg芬太尼、0.02mg/kg芬太尼或1.5mg/kg赛拉嗪与生理盐水,并分别用芬太尼、赛拉嗪或两者进行测试,观察药物是否与训练剂量产生交叉反应。使用全身体积描记法评估赛拉嗪对呼吸的影响。
赛拉嗪降低了运动活性和核心体温,但个体间存在较大差异。在一些个体中,赛拉嗪完全替代了芬太尼,并延长了芬太尼的主观效应。1mg/kg和1.78mg/kg的赛拉嗪剂量仅部分与1.5mg/kg的训练剂量产生交叉反应。赛拉嗪加剧了阿片类药物的呼吸抑制作用,而阿替美唑可逆转赛拉嗪增强的吗啡诱导的呼吸抑制。
赛拉嗪给药后,在多种行为指标上观察到个体差异,这可能重现了吸毒者中报告的赛拉嗪的分歧性。